All In Biotech

NDA 019445 · Hospira

Dextrose 50%

Dextrose · Injection

Last checked: Nov 20, 2026Latest source record: Jul 25, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1986

Jun 3, 1986

Approved uses

3

Original approval plus efficacy supplements

Registered trials

3,798

712 Phase 3, 360 recruiting

FAERS reports

13,927

12,868 serious, 2,115 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 14, 2026.

Dextrose (50%) Injection is indicated for the treatment of insulin-induced hypoglycemia (e.g., hyperinsulinemia, insulin shock) in adults and pediatric patients 2 years of age and older. Dextrose Injection (50%) is indicated for the treatment of insulin-induced hypoglycemia (e.g., hyperinsulinemia, insulin shock) in adults and pediatric patients 2 years of age and older. ( 1 )

Mechanism: Dextrose restores blood glucose levels and provides a source of carbohydrate calories.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 23, 1998 Supplement 6 · Efficacy
  • Nov 23, 1998 Supplement 4 · Efficacy
  • Jun 3, 1986 Original approval · Type 5 - New Formulation or New Manufacturer
2 products under this application
  • DEXTROSE 50% · DEXTROSE 500MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
  • DEXTROSE 25% · DEXTROSE 250MG/ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Dextrose" as an intervention, any sponsor and status, largest first.

All 3,798 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • myelosuppression1,929
  • off label use1,093
  • nausea1,045
  • drug ineffective974
  • vomiting968
  • acute kidney injury809
  • white blood cell count decreased756
  • pyrexia742
  • dyspnoea694
  • sepsis588
  • abdominal pain544
  • hypotension535

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200453
200536
200649
200740
200864
200983
2010117
2011145
2012148
2013128
2014396
2015201
2016313
2017284
2018381
2019488
2020611
2021965
20221,714
20232,042
20241,959
20251,991
20261,717

Recalls

2 FDA enforcement reports for this application.

  • Nov 27, 2019 · Class II · Terminated

    Labeling: Incorrect or Missing Lot and/or expiration date.

  • Apr 21, 2017 · Class I · Ongoing

    Presence of Particulate Matter: human hair found within an internal sample syringe.

Shortages

FDA's drug shortage list.

  • Current · updated Nov 9, 2026

    Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-7517-16). Other

  • Current · updated Nov 9, 2026

    Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-6648-02). Other

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,414 on PubMed

Sponsor: Pfizer · Also marketed as Dextrose 25%

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.